1-5 of 5
Richard P. Beckmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Free
Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Carlos Marugán, Karsten Boehnke, Carmen Baquero, Yu-Hua Hui, Sonya C. Chapman, Yanzhu Yang, Yi Zeng, Sarah M. Bogner, Robert T. Foreman, Andrew Capen, Gregory P. Donoho, Robert D. Van Horn, Darlene S. Barnard, Jack A. Dempsey, Richard P. Beckmann, Mark S. Marshall, Li-Chun Chio, Yuewei Qian, Yue W. Webster, Amit Aggarwal, Shaoyou Chu, Shobha Bhattachar, Louis F. Stancato, Michele S. Dowless, Phillip W. Iversen, Jason R. Manro, Jennie L. Walgren, Bartley W. Halstead, Matthew Z. Dieter, Ricardo Martinez, Shripad V. Bhagwat, Emiko L. Kreklau, Maria Jose Lallena, Xiang S. Ye, Bharvin K.R. Patel, Christoph Reinhard, Gregory D. Plowman, David A. Barda, James R. Henry, Sean G. Buchanan, Robert M. Campbell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2207–2219.
https://doi.org/10.1158/1535-7163.MCT-18-0529
Published: 02 December 2019
View article titled, Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Open the PDF for Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy in another window
Includes: Supplementary data
Journal Articles

The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

Free
Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Horn, Youyan Zhang, Sean G. Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann, Sheng-Bin Peng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (10): 2253–2263.
https://doi.org/10.1158/1535-7163.MCT-14-0257
Published: 02 October 2014
View article titled, The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
Open the PDF for The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation in another window
Includes: Supplementary data
Journal Articles

Abstract C88: The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.

Free
Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Hoen, Youyan Zhang, Sean Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann, Sheng-Bin Peng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C88.
https://doi.org/10.1158/1535-7163.TARG-13-C88
Published: 01 November 2013
View article titled, Abstract C88: The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Journal Articles

Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents.

Free
Samuel C. McNeely, Teresa F. Burke, Sara DurlandBusbice, Darlene S. Barnard, Mark S. Marshall, Aimee K. Bence, Richard P. Beckmann
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A108.
https://doi.org/10.1158/1535-7163.TARG-11-A108
Published: 12 November 2011
View article titled, Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents.
Journal Articles

The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines

Free
Chafiq Hamdouchi, Heather Keyser, Elizabeth Collins, Carlos Jaramillo, Jose Eugenio De Diego, Charles D. Spencer, Jack Alan Dempsey, Bryan D. Anderson, Tillie Leggett, Nancy B. Stamm, Richard M. Schultz, Scott A. Watkins, Kim Cocke, Stephanie Lemke, Teresa F. Burke, Richard P. Beckmann, Jeffrey T. Dixon, Thomas M. Gurganus, Nancy B. Rankl, Keith A. Houck, Faming Zhang, Michal Vieth, Juan Espinosa, David E. Timm, Robert M. Campbell, Bharvin K. R. Patel, Harold B. Brooks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (1): 1–9.
https://doi.org/10.1158/1535-7163.1.3.1
Published: 28 January 2004
View article titled, The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines
Open the PDF for The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines in another window